Physicans preparing to deal with the anticipated spread of the novel influenza A(H1N1) virus are awaiting the results of a series of U.S. clinical trials aimed at gathering critical data about two candidate vaccines, amid concerns that vaccination efforts could be delayed by manufacturing issues.
PREVIEW